Criteria

The European League Against Rheumatism and American College of Rheumatology (EULAR/ACR) classification criteria for adult and juvenile idiopathic inflammatory myopathies (IIMs)[123]

Partially validated criteria for diagnosis of 'definite', 'probable', and 'possible' IIM; and the major subgroups of IIM, including DM, amyopathic DM, and juvenile DM.

Points are allocated as follows for different variables, with or without muscle biopsy.

An online scoring calculator is available: Classification criteria for IIMs Opens in new window

  • Age of onset

    • Age of onset of first symptom assumed to be related to the disease ≥18 years and <40 years

      • With muscle biopsy: 1.3

      • Without muscle biopsy: 1.5

    • Age of onset of first symptoms assumed to be related to the disease ≥40 years

      • With muscle biopsy: 2.1

      • Without muscle biopsy: 2.2

  • Muscle weakness

    • Objective symmetric weakness, usually progressive, of the proximal upper extremities

      • With muscle biopsy: 0.7

      • Without muscle biopsy: 0.7

    • Objective symmetric weakness, usually progressive, of the proximal lower extremities

      • With muscle biopsy: 0.8

      • Without muscle biopsy: 0.5

    • Neck flexors are relatively weaker than neck extensors

      • With muscle biopsy: 1.9

      • Without muscle biopsy: 1.6

    • In the legs, proximal muscles are relatively weaker than distal muscles

      • With muscle biopsy: 0.9

      • Without muscle biopsy: 1.2

  • Skin manifestations

    • Heliotrope rash

      • With muscle biopsy: 3.1

      • Without muscle biopsy: 3.2

    • Gottron's papules

      • With muscle biopsy: 2.1

      • Without muscle biopsy: 2.7

    • Gottron's sign

      • With muscle biopsy: 3.3

      • Without muscle biopsy: 3.7

  • Other clinical manifestations

    • Dysphagia or oesophageal dysmotility

      • With muscle biopsy: 0.7

      • Without muscle biopsy: 0.6

  • Laboratory measures

    • Anti-histidyl-tRNA synthetase (anti-Jo-1) autoantibody present

      • With muscle biopsy: 3.9

      • Without muscle biopsy: 3.8

    • Elevated serum levels of creatine kinase or lactate dehydrogenase or aspartate aminotransferase or alanine aminotransferase

      • With muscle biopsy: 1.3

      • Without muscle biopsy: 1.4

Additional points are allocated as follows if muscle biopsy features the presence of:

  • Endomysial infiltration of mononuclear cells surrounding, but not invading, myofibres: 1.7

  • Perimysial and/or perivascular infiltration of mononuclear cells: 1.2

  • Perifascicular atrophy: 1.9

  • Rimmed vacuoles: 3.1.

Scoring

  • Probability of IIM including muscle biopsy = 1/[1+exponential (5.33–score)] or

  • Probability of IIM without muscle biopsy = 1/[1+exponential (6.49–score)]

  • ≥50% and <55% = possible IIM

  • ≥55% and <90% = probable IIM

  • ≥90% = definite IIM.

Patients classified with IIM by the EULAR/ACR classification criteria can be further subclassified using a classification tree that includes:

  • Amyopathic DM

  • DM

  • Inclusion body myositis

  • Immune-mediated necrotising myopathy

  • Juvenile DM

  • Polymyositis.

Commonly used severity criteria for idiopathic inflammatory myopathies

  • Severe disease: includes those with severe muscle weakness (e.g., quadriplegia), interstitial lung disease, myocarditis, respiratory failure, severe dysphagia, or other life-threatening complications.

  • Non-severe disease: includes those with muscle strength of ≥4/5 and none of the life-threatening complications of severe disease.

Use of this content is subject to our disclaimer